N-{6-[(9H-fluoren-9-yl)dimethylazaniumyl]hexyl}-N,N-dimethyl-9H-fluoren-9-aminium dibromide

• ChemBase ID: 817
• Molecular Formular: C36H42Br2N2
• Molecular Mass: 662.54008
• Monoisotopic Mass: 660.17147335
• SMILES: [Br-].[Br-].c1cccc2c1c1c(cccc1)C2[N+](CCCCCC[N+](C1c2ccccc2c2ccccc12)(C)C)(C)C
• Canonical SMILES: C[N+](C1c2ccccc2c2c1cccc2)(CCCCCC[N+](C1c2ccccc2c2c1cccc2)(C)C)C.[Br-].[Br-]
• InChI: InChI=1S/C36H42N2.2BrH/c1-37(2,35-31-21-11-7-17-27(31)28-18-8-12-22-32(28)35)25-15-5-6-16-26-38(3,4)36-33-23-13-9-19-29(33)30-20-10-14-24-34(30)36;;/h7-14,17-24,35-36H,5-6,15-16,25-26H2,1-4H3;2*1H/q+2;;/p-2
• InChIKey: WDEFPRUEZRUYNW-UHFFFAOYSA-L

NAMES AND DATABASE IDS

Names

• IUPAC name: N-{6-[(9H-fluoren-9-yl)dimethylazaniumyl]hexyl}-N,N-dimethyl-9H-fluoren-9-aminium dibromide
• IUPAC Traditional name: N-[6-(9H-fluoren-9-yldimethylaminio)hexyl]-N,N-dimethyl-9H-fluoren-9-aminium dibromide
• Brand Name: Mylaxen; Milaxen
• Synonyms: Hexafluorenium bromide; Hexafluorenium; Hexafluronium bromide; Hexafluronium

Database IDs

• CAS Number: 317-52-2
• PubChem SID: 46507171; 160964280
• PubChem CID: 9434

CALCULATED PROPERTIES

• Acid pKa: 16.639652
• H Acceptors: 0
• H Donor: 0
• LogD (pH = 5.5): -0.2840138
• LogD (pH = 7.4): -0.2840138
• Log P: -0.2840138
• Molar Refractivity: 184.4936 cm^3
• Polarizability: 65.706406 Å^3
• Polar Surface Area: 0.0 Å^2
• Rotatable Bonds: 9
• Lipinski's Rule of Five: false

PROPERTIES

Physical Property

• Hydrophobicity(logP): -0.06

DETAILS

DrugBank - DB00941

• Drug Groups: approved
• Description: Hexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery. It is known to bind and block the activity of plasma cholinesterases.
• Indication: Used as an adjunct with succinylcholine (or suxamethonium chloride) to prolong muscle relaxation and to prevent succinylcholine-induced muscle fasciculations.
• Pharmacology: Hexafluronium bromide is a cholinesterase antagonist that can be used to prolong the relaxation effects of succinylcholine or suxamethonium chloride. Suxamethonium acts as a depolarizing muscle relaxant. It imitates the action of acetylcholine at the neuromuscular junction and is degraded by pseudocholinesterase, a plasma cholinesterase. The prolonged stimulation of the acetylcholine receptor results first in disorganized muscle contractions, then in profound relaxation. Cholinesterases catalyze the hydrolysis of the neurotransmitter acetylcholine into choline and acetic acid, a reaction necessary to allow a cholinergic neuron to return to its resting state after activation. There are two types of cholinesterase acetylcholinesterase and pseuodocholinesterase. The first hydrolyses acetylcholine more quickly; the latter hydrolyses butyrylcholine and succinylcholine more quickly. An absence or mutation of the pseudocholinesterase enzyme leads to a medical condition known simply as pseudocholinesterase deficiency. This is a silent condition that only manifests itself when people who have the deficiency receive the muscle relaxants succinylcholine or mivacurium during a surgery.
• Toxicity: LD₅₀ = 280 mg/kg (mouse, oral)
• Affected Organisms: Humans and other mammals
• External Links: Wikipedia